MAPT and Alzheimer disease: The effects of C1 on three AD animal models, which represent beta-amyloid precursor protein (APP) pathology (5xFAD mice), tauopathy (P301S mice) and the APP/Tau combined pathology (3xTg-AD mice), were investigated.